Complement in Medical Technology
Navigation Links
Complement in Medical Technology
... affected by it."
About POT-4
POT-4 is a complement factor C3 inhibitor, which shuts down the complement activation cascade that could otherwise lead to ... "dry" form of the disease.
About the complement System and POT-4 ...
... other chronic diseases involving the alternative complement system, announced today that the Canadian Patent ... genetic modifications in several genes including complement factor H (CFH), complement factor B ...
... titled, "Safety and Efficacy of the Terminal complement Inhibitor Eculizumab in Japanese Patients with ... et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of ... (2) Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal ...
... Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, ... patients with aHUS are missing or have defective complement inhibitors that help to regulate the body's ... attack on their red blood cells leading to severe complement activation and hemolysis (destruction of those ...
... were presented at the XXII International complement Workshop in Basel, Switzerland. The data ... expertise and expanding knowledge base within the complement research community," said Michael Holers, M.D., ... of the effects of modulation of the complement system on animal models of human disease," said ...
... First complement inhibitor to be tested in AMD patients ... safety results in its Phase I study. POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to ...
... be presented next week at the XXII International complement Workshop in Basel, Switzerland. The data, which ... and the company's academic collaborators in the complement research community. Five studies testing the ... Taligen's approach that targeting the alternative complement pathway can impact ...
... will be presented at the XXII International complement Workshop in Basel, Switzerland, September ... of C3, the hub of the complement cascade. complement protein C3 is the master regulator of complement ... proteins for the controlled depletion of complement protein C3. The therapeutic potential for ...
... that Modulate Alternative Pathway of complement System CAMBRIDGE, Mass., July 23 /PRNewswire/ ... that are closely aligned with an international complement biology research network organized by Michael ... to modulate the alternative pathway of the complement system," said Dr. Emlen. "We are currently ...
... events over time. -- An increase in C3 and C4 complement among patients with low complement at baseline. About the Phase 2 Study of ... normalization of autoantibody, immunoglobulin and complement levels over three years of treatment ...
... Company will also require, at a minimum, one additional Phase III study to complement study IT-A-008 in order to pursue FDA approval and licensure. Update ... ability to complete, at a minimum, an additional Phase III study to complement study IT-A-008 in order to pursue FDA approval and licensure, the ...
... Detection may be used to complement and target screening for the disease; findings will be integrated into ... the detection of these and other risk variants will soon be employed to complement the assessment of standard risk factors for bladder cancer. As with all of ...
... mg tid (three times daily). The data from the 111 and 112 studies will complement the results of a 2-week ABPM study with naproxcinod compared to naproxen ... at the American Heart Association (AHA) in November 2007. They will also complement the Office Blood Pressure Measurements (OBPMs) being collected in each of ...
... 2007; 100:4123-4128. (6)Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J ... Brodsky RA, Young NS, Antonioli E et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal ...
... RA, Young, NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal ... 2008;111:1840-1847. (2) Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl ...
... Young, NS, Antonioli E., et al. Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal ... browser window.) (2) Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl ...
... online publication in Blood, titled "Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal ... 2005;106:3699-3709. (4) Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J ...
... at baseline normalized at Weeks 52-128. -- An increase in C3 and C4 complement among patients with low complement at baseline. -- Reversion of autoantibody levels from positive to ...
... to working with the agency throughout the review process," said Cynthia Schwalm, President of Eisai Inc. "This application is one part of a full complement of clinical development programs we have committed for Dacogen and is a vital part of our human health care mission of increasing patient benefits ...
... including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company's focus in specialty-driven markets, particularly neuroscience and hospital. King's wholly-owned subsidiary, Alpharma, Inc., is also a ...
... The design also allows implants to be cut to length and easily hydrated with autologous blood products. The Company has also developed a full complement of specialized instruments to prepare the defect site for delivery of this proprietary bi-phasic implant. The Company is currently in discussion ...
... which plans to file a Biologic License Application (BLA) for NT-201 in the USA in the near future. "The data to be presented at AAN complement the European data. We now have robust U.S. data for Xeomin (the brand name for NT-201 in Europe) for the symptomatic management of movement ...
... a small-scale safety and tolerability trial of Dimebon added to donepezil, which found the combination to be well tolerated. CONCERT is designed to complement previous and ongoing studies by further evaluating the efficacy of Dimebon. The Phase 3 program also includes the confirmatory 6-month CONNECTION ...
... funding and expertise can make the greatest difference in speeding scientific developments toward the clinic and patients." Critical Challenges complement the Foundation's annually recurring Pipeline Programs, which do not identify a specific research priority area to be pursued, but instead provide ...
... disease fitting within Transgenomic's focus on disorders originating from mitochondrial damage. NuroPro will add significant depth to complement our array of genetic tests in neurology." Power3 Medical CEO Helen R. Park said, "This new licensing agreement provides Transgenomic with the ...
... The data indicate that the HeartMate II achieved statistical superiority to the control group patients by an overwhelming margin. These findings complement the experience with the device in bridge-to-transplantation (BTT) patients, both in our pivotal trial and as a commercially available device since ...
... at 8:30am ET on Monday, November 10. The webcast will be archived for 30 days following the presentation. About VIA-2291 VIA-2291 is designed to complement current standard of care therapies that treat cardiac risk factors, such as statins, antiplatelet and blood pressure medications. VIA-2291 is ...
... metabolism. Based on the strength of these results and the unique Empatic mechanism of action, the Company selected this product combination to complement our Contrave clinical development program. Forward-Looking Statements Orexigen cautions you that statements included in this press release that ...
... other chronic diseases involving the alternative complement system, announced today that the Canadian Patent ... genetic modifications in several genes including complement factor H (CFH), complement factor B ...
... titled, "Safety and Efficacy of the Terminal complement Inhibitor Eculizumab in Japanese Patients with ... et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of ... (2) Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal ...
... Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, ... patients with aHUS are missing or have defective complement inhibitors that help to regulate the body's ... attack on their red blood cells leading to severe complement activation and hemolysis (destruction of those ...
... were presented at the XXII International complement Workshop in Basel, Switzerland. The data ... expertise and expanding knowledge base within the complement research community," said Michael Holers, M.D., ... of the effects of modulation of the complement system on animal models of human disease," said ...
... First complement inhibitor to be tested in AMD patients ... safety results in its Phase I study. POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to ...
... be presented next week at the XXII International complement Workshop in Basel, Switzerland. The data, which ... and the company's academic collaborators in the complement research community. Five studies testing the ... Taligen's approach that targeting the alternative complement pathway can impact ...
... will be presented at the XXII International complement Workshop in Basel, Switzerland, September ... of C3, the hub of the complement cascade. complement protein C3 is the master regulator of complement ... proteins for the controlled depletion of complement protein C3. The therapeutic potential for ...
... that Modulate Alternative Pathway of complement System CAMBRIDGE, Mass., July 23 /PRNewswire/ ... that are closely aligned with an international complement biology research network organized by Michael ... to modulate the alternative pathway of the complement system," said Dr. Emlen. "We are currently ...
... events over time. -- An increase in C3 and C4 complement among patients with low complement at baseline. About the Phase 2 Study of ... normalization of autoantibody, immunoglobulin and complement levels over three years of treatment ...
... Company will also require, at a minimum, one additional Phase III study to complement study IT-A-008 in order to pursue FDA approval and licensure. Update ... ability to complete, at a minimum, an additional Phase III study to complement study IT-A-008 in order to pursue FDA approval and licensure, the ...
... Detection may be used to complement and target screening for the disease; findings will be integrated into ... the detection of these and other risk variants will soon be employed to complement the assessment of standard risk factors for bladder cancer. As with all of ...
deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia
... Findings may provide the foundation for a test to complement standard clinical diagnosis, potentially enabling earlier intervention and ... them a valuable basis upon which to develop molecular diagnostic tests to complement standard clinical diagnosis. The study, 'Large recurrent microdeletions ...... mg tid (three times daily). The data from the 111 and 112 studies will complement the results of a 2-week ABPM study with naproxcinod compared to naproxen ... at the American Heart Association (AHA) in November 2007. They will also complement the Office Blood Pressure Measurements (OBPMs) being collected in each of ...
... 2007; 100:4123-4128. (6)Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J ... Brodsky RA, Young NS, Antonioli E et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal ...
... RA, Young, NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal ... 2008;111:1840-1847. (2) Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl ...
... Young, NS, Antonioli E., et al. Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal ... browser window.) (2) Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl ...
... online publication in Blood, titled "Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal ... 2005;106:3699-3709. (4) Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J ...
... at baseline normalized at Weeks 52-128. -- An increase in C3 and C4 complement among patients with low complement at baseline. -- Reversion of autoantibody levels from positive to ...
Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
... ophthalmic diseases, and it also intends to market diagnostic systems that complement its therapeutic products. The company recently announced it has entered ... for opthalmic diseases, our ability to market diagnostic systems that complement our therapeutic products, as well as other non-historical statements about ...... to working with the agency throughout the review process," said Cynthia Schwalm, President of Eisai Inc. "This application is one part of a full complement of clinical development programs we have committed for Dacogen and is a vital part of our human health care mission of increasing patient benefits ...
Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
... including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company's focus in specialty-driven markets, particularly neuroscience and hospital. King's wholly-owned subsidiary, Alpharma, Inc., is also a ...... including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company's focus in specialty-driven markets, particularly neuroscience and hospital. King's wholly-owned subsidiary, Alpharma, Inc., is also a ...
In Rare Disorder, a Familiar Protein Disrupts Gene Function
... The researchers used DNA microarrays, manufactured chips that measure how strongly different genes are expressed throughout a cell's full complement of DNA. The study team identified hundreds of genes that were dysregulated compared to controls, and also detected gene expression profiles that were ...... The design also allows implants to be cut to length and easily hydrated with autologous blood products. The Company has also developed a full complement of specialized instruments to prepare the defect site for delivery of this proprietary bi-phasic implant. The Company is currently in discussion ...
TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
... treatment, including agents that inhibit angiogenesis. TRACON addresses unmet needs in these areas with first-in-class product candidates that will complement existing therapies. TRC093 is a monoclonal antibody that binds to cleaved collagen to inhibit angiogenesis and tumor growth that began dosing in a ...... which plans to file a Biologic License Application (BLA) for NT-201 in the USA in the near future. "The data to be presented at AAN complement the European data. We now have robust U.S. data for Xeomin (the brand name for NT-201 in Europe) for the symptomatic management of movement ...
... a small-scale safety and tolerability trial of Dimebon added to donepezil, which found the combination to be well tolerated. CONCERT is designed to complement previous and ongoing studies by further evaluating the efficacy of Dimebon. The Phase 3 program also includes the confirmatory 6-month CONNECTION ...
... funding and expertise can make the greatest difference in speeding scientific developments toward the clinic and patients." Critical Challenges complement the Foundation's annually recurring Pipeline Programs, which do not identify a specific research priority area to be pursued, but instead provide ...
Astrocytes Help Separate Man From Mouse
... participants in brain function and sensory processing." The brain's two signaling systems - one composed of neurons, and one of astrocytes - complement each other, Nedergaard said. Neurons send signals extremely quickly over long distances - the hand touches a hot stove, for instance, and the brain ...FDA Submission of B-R-A-H-M-S MR-proANP Kryptor
... meeting, the results of the BACH-trial confirm the company's commitment to improving healthcare through highly effective biomarker tests and complement the success of the Procalcitonin Kryptor, the company's test for the diagnosis of severe bacterial infections, introduced in the U.S. in early 2008. ...Kensey Nash Announces IDE Submission for Cartilage Repair Device
... The design also allows implants to be cut to length and easily hydrated with autologous blood products. The Company has also developed a full complement of specialized color-coded instruments to estimate implant size and prepare the defect site for the delivery of this proprietary bi-phasic implant. ...... disease fitting within Transgenomic's focus on disorders originating from mitochondrial damage. NuroPro will add significant depth to complement our array of genetic tests in neurology." Power3 Medical CEO Helen R. Park said, "This new licensing agreement provides Transgenomic with the ...
Breakthrough in Prenatal Screening for Down Syndrome
... and negatives drives better patient care, and that's exciting for the future." "Our preliminary results are extraordinarily encouraging, and complement nicely the work of other investigators whose efforts have focused heretofore in the 2nd trimester," said Lenetix president and CEO Leonard H. ....Gene Abnormality Found to Predict Childhood Leukemia Relapse
... disease. And, indeed, it did." The researchers' analysis indicated that identifying IKAROS alterations may be clinically useful and will complement existing diagnostic tests and measurement of minimal residual disease levels. While a clinical test for alterations of IKAROS could prove ...... The data indicate that the HeartMate II achieved statistical superiority to the control group patients by an overwhelming margin. These findings complement the experience with the device in bridge-to-transplantation (BTT) patients, both in our pivotal trial and as a commercially available device since ...
... at 8:30am ET on Monday, November 10. The webcast will be archived for 30 days following the presentation. About VIA-2291 VIA-2291 is designed to complement current standard of care therapies that treat cardiac risk factors, such as statins, antiplatelet and blood pressure medications. VIA-2291 is ...
Raptor Pharmaceuticals Provides Update on Targeting Platforms
... bind better and demonstrate enhanced biological potency compared to proteins or peptides derived from the naturally occurring RAP sequence and will complement our growing in-house set of targeting peptides." Raptor also announced that the Patent Office of Japan will issue Raptor's patent application ...ORBIS and Alcon Call Attention to the Aging Eye
... ORBIS Flying Eye Hospital and through ORBIS-sponsored hospital-based programs in China, Ethiopia, India, Peru and other countries. These engineers complement the hundreds of volunteer doctors and nurses who make ORBIS' medical training possible. Since 1979, Alcon has provided more than $8 million in ...... metabolism. Based on the strength of these results and the unique Empatic mechanism of action, the Company selected this product combination to complement our Contrave clinical development program. Forward-Looking Statements Orexigen cautions you that statements included in this press release that ...
Other ContentsaspirinaspirinaspirinaspirinchildrenchildrenchildrenchildrenchildrenchildrenchildrenchildrenchildrenastigmatismastigmatismasymptomaticasymptomaticasymptomaticasymptomaticataxiaataxiaataxiaatelectasisatherosclerosisatherosclerosisatherosclerosisOther TagsvousvousChrisChrisOther Tagsorganizing 2organizing 3hybrid 2hybrid 3hybrid 4malfunctioning 2changed 2changed 3changed 4changed 5changed 6changed 7changed 8changed 9beneath 2beneath 3discovering 2discovering 3
(Date:11/25/2009)... September 11, firefighters, police officers and a...in the World Trade Center complex. They battled to...ched for survivors, tackled fires and evacuated as...ned an estimated 17,000 people. And making their j...ions: frightened workers and their relatives jamme...
(Date:11/25/2009)...er the course of a lifetime, the heart pumps some ...he order to do this, the muscle fibers of the hear... headed by Dr. Wolfgang Rottbauer, vice chair of t...sity Hospital (Chairman: Prof. Dr. H. A. Katus), h...e stability of the smallest muscular unit, the sar...
(Date:11/24/2009)...r thousands of years it has been prescribed by tra...ments from headaches and stomach pain to fever and...wcastle University have been able to scientificall...renata otherwise known as Brazilian mint. , Tes... team led by researcher Graciela Rocha was able to...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3New genetic cause of cardiac failure discovered 2Got a pain? -- Have a cup of Brazilian mint 2SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 1SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 2SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 3SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 4National Investigational Trial for Emergency Stroke Care At CDH 3A One Illinois Hospital Tests New Device That May Reverse Brain Damage Up to 24 Hours 5410 1National Investigational Trial for Emergency Stroke Care At CDH 3A One Illinois Hospital Tests New Device That May Reverse Brain Damage Up to 24 Hours 5410 2National Investigational Trial for Emergency Stroke Care At CDH 3A One Illinois Hospital Tests New Device That May Reverse Brain Damage Up to 24 Hours 5410 3New Editor Named for International Journal Of Nursing Terminologies 26amp 3B Classifications 59323 1New Editor Named for International Journal Of Nursing Terminologies 26amp 3B Classifications 59323 2(Date:11/27/2009)... Three new interactive anatomy education app...ins expand health sciences learning opportunities ... Durham, NC (Vocus) November 27, 2009 -- Modali...WW), a division of Wolters Kluwer Health, today an...ation apps on the App Store. Clemente’s Anat...
(Date:11/26/2009)....J.,Nov.27/PRNewswire/--Thediabetespopulationinthe...nnualmedicalspendingonthediseaseisprojectedtohit$3...publishedintheDecemberissueof DiabetesCare .TheNat...mofNovoNordisk,commissionedtheanalysisbyateamfromt...t,thenumberofAmericanslivingwithdiabeteswillrisefr...
(Date:11/26/2009)...tering drug tetrathiomolybdate (TM) has been shown...lson disease, a disease caused by an overload of c...s known. Very little, however, is known about how ...tudy led by Northwestern University researchers no...sional structure of TM bound to copper-loaded meta...
(Date:11/26/2009)...hrill when on an emotional rollercoaster, study fi...s) -- Call it the fear factor meets the jubilant s...rs -- especially those who root for the winning te...osely contested match and victory was in doubt, pr...hew on that this Thanksgiving weekend as you,re gl...
(Date:11/26/2009)... Dr. David Kim of the Live Life Again Center...as , is one of a growing number of physicians who ... sites to connect with individuals who are interes...bid obesity. Dr. Kim is utilizing Facebook to shar...s practice with the community. , ...
Breaking Medicine News(10 mins):Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3[0] Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store[1] Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows[1] Research sheds light on workings of anti-cancer drug[0] Watching the Nail-Biting Big Game Hurts So Good[1] Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |